Intra-Individual Comparative Study of Methotrexate Versus Triamcinolone Acetonide Delivered via Microneedling for Recalcitrant Alopecia Areata

This study introduced a non-invasive, three-step diagnostic algorithm for alopecia that combines clinical and trichoscopic features to accurately identify alopecia subtypes, potentially reducing reliance on invasive histopathology.

This review explores the mechanisms, techniques, and clinical applications of microneedling, highlighting its advantages and challenges in skin rejuvenation, and discusses future innovations in the field as it continues to evolve.

This study reviewed 39 studies with 3204 patients to identify characteristic trichoscopic findings in alopecia areata, highlighting yellow and black dots, broken, short vellus, and tapering hairs as key indicators. It found no single diagnostic trichoscopic finding but observed trichoscopy's utility in monitoring treatment response.

In this study, both intralesional and microneedling treatments with triamcinolone acetonide significantly reduced alopecia areata markers, but their clinical responses did not differ significantly, suggesting microneedling as a safe, cost-effective option with minimal complications.

This study found that micro-needling with triamcinolone acetonide led to the best treatment outcomes for alopecia areata compared to other methods of trans-epidermal drug delivery.

In this study, microneedling and intralesional corticosteroid injections in patients with alopecia areata showed similar hair regrowth effectiveness, with microneedling resulting in more uniform but less dense regrowth and fewer side effects.

This study presents two cases where intralesional methotrexate combined with ablative fractional CO2 laser treatment resulted in excellent outcomes for refractory alopecia areata.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

This study found that intralesional triamcinolone acetonide was more effective than saline for hair regrowth in scalp alopecia areata, with 10 mg/mL showing the best response but more side effects.

This study reviewed recent theories on alopecia areata's pathogenesis, highlighting its autoimmune nature due to immune privilege disruption in hair follicles, and noted current treatments have limited efficacy with high relapse rates, underscoring the need for further research into its mechanisms for better therapies.

This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.

In this retrospective study, low-dose methotrexate was observed to be effective and well-tolerated in treating recalcitrant alopecia areata multiplex, achieving complete or near-complete hair regrowth in about 90% of patients despite some experiencing elevated liver enzymes and gastrointestinal discomfort.

This review explores multidisciplinary advances in understanding alopecia areata, including epidemiology, pathogenesis, and innovative treatments, but reports no new research results.

This review discusses treatment options for alopecia areata and suggests tailored treatment plans, noting the challenges posed by spontaneous remission and limited high-quality clinical trials.